Professor of Oncology
Member, Breast Cancer Program
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Dr. Wolff serves as the Executive Officer of the Translational Breast Cancer Research Consortium (TBCRC) (www.tbcrc.org), a clinical research consortium, initiated in 2005 with support from BCRF that unites the efforts of many leading breast cancer programs from top academic medical centers throughout the United States. The Consortium, led by laboratory scientists and clinical researchers, pursues focused clinical trials that integrate clinical and laboratory studies in an effort to accelerate progress in breast cancer clinical research. Since its inception, 37 TBCRC clinical trials have been approved, 24 of which have been completed/closed to accrual. Results from the first 16 completed TBCRC trials – four in triple negative breast cancer, four in HER2 positive disease, one in endocrine resistant disease, two in hormone receptor (HR) negative breast cancer, one in HER2 negative breast cancer, one in premalignant luminal disease, and three non-therapeutic trials– have been presented at national meetings. The clinical results, as well as some correlative work, from eleven TBCRC trials have been published in peer-reviewed journals, such as the Journal of Clinical Oncology, Science Signaling, Clinical Cancer Research, Cancer Research, Breast Cancer Research and Treatment, Journal of Nuclear Medicine, Annals of Surgical Oncology, and Cancer. TBCRC trials continue to provide insight in the development of more effective and individualized treatments for various subtypes of breast cancer. Funding from BCRF remains critical to bring together scientific resources and researchers to develop new strategies to reduce the burden of breast cancer.
The TBCRC network is engaged in other BCRF-funded studies including the Male Breast Cancer International Project (lead investigators, Fatima Cardoso, John Bartlett, Sharon Giordano, John Bartlett and Peggy Porter and the Evelyn H. Lauder Founder’s Fund (lead investigators, Martine Piccart, Breast International Group, and Nancy Davidson on behalf of North American Breast Cancer Group).
The Evelyn H. Lauder Founder’s Fund is an international initiative that was created from the outpouring of contributions to BCRF in honor of Mrs. Lauder, who died in 2011. The objective of the multi-year project is to dissect the molecular underpinning of metastasis. BCRF grantee and member of the Scientific Advisory Board, Dr. Nancy Davidson, leads the US clinical trials group (known as AURORA US) under the administrative oversight of the TBCRC, with BCRF grantee Charles Perou overseeing the molecular studies along with contributions from Matthew Ellis, Nancy Lin, Andrea Richardson, William F. Symmans and others. The AURORA US effort was initiated in mid-2014. Its goal is to identify the molecular features behind the development and progression of metastatic disease and resistance to therapy. Two main efforts are underway. One is to conduct in-depth studies of breast cancer metastases from tissues collected from patients with advanced stages of metastatic disease. Another is to identify patients with metastatic disease who are earlier in their course of treatment. This intensive strategy will allow AURORA US investigators to better understand the driving forces behind this life-threatening stage of breast cancer and to devise preventive interventions and new treatments. Such studies cannot be done by a single institution, and the Founder’s Fund Aurora US effort has allowed some of the most innovative researchers in the US to join forces and collaborate to better understand this disease.
Antonio Wolff is a Professor of Oncology at the Johns Hopkins University School of Medicine, a member of the Breast and Ovarian Cancer Program at the Johns Hopkins Kimmel Comprehensive Cancer Center, and a breast cancer medical oncologist with expertise in clinical trials, biomarkers development and implementation, survivorship, and clinical practice guidelines. Dr .Wolff received his medical degree from the Universidade Federal do Rio de Janeiro, completed a residency at Mount Sinai (NY) and fellowship at Johns Hopkins. His expertise is in collaborative research in breast cancer clinical trials, the integration of research findings into clinical practice, biomarker development and implementation, and in quality initiatives. Dr. Wolff was a member of the Breast Cancer Guidelines Committee of the National Comprehensive Cancer Network between 2000 and 2014. He sat on the Clinical Practice Guidelines Committee of the American Society of Clinical Oncology from 2002 to 2008 (Chair, 2006-2007), and was a member of the first ASCO Quality Care Committee. Dr. Wolff is also interested in survivorship, needs assessments, and educational needs of breast cancer patients. At Johns Hopkins, he co-chairs the Cancer Outcomes & Health Services Research Interest Group. He chaired the Cancer Center Clinical Research Scientific Review Committee and was a member of the School of Medicine CME Advisory Board. Since 2006, he has been Executive Officer of the Translational Breast Cancer Research Consortium (www.tbcrc.org), a clinical research consortium that involves all breast cancer SPOREs and major academic breast cancer programs. Dr. Wolff has received research funding from the National Cancer Institute, Avon Foundation, Breast Cancer Research Foundation, and Susan G. Komen Breast Cancer Foundation. In January 2014 he became Co-Chair of the Breast Cancer Committee of ECOG-ACRIN. He is Associate Editor of the Journal of Clinical Oncology